Scilex Holding (SCLX) Other Non Operating Income (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Other Non Operating Income of $25.7 million for Q1 2026, up 147.2% year-over-year from $10.4 million in Q1 2025, and up 36.53% quarter-over-quarter from $18.8 million in Q4 2025.
Scilex Holding (SCLX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Scilex Holding's Other Non Operating Income history runs 6 years deep, the most recent figure standing at $25.7 million for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 147.2% year-over-year to $25.7 million; the TTM figure through Mar 2026 stood at -$26.2 million (down 188.3% YoY), while the FY2025 annual figure was $21.8 million, up 25.29% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $25.7 million, up from $18.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $33.4 million in Q3 2022, with the low at -$58.4 million in Q3 2025.
- The 5-year median for Other Non Operating Income is $2.4 million (2022), against an average of $3.1 million.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income soared 2775.21% in 2022, then slumped 126763.04% in 2025.
- Scilex Holding's Other Non Operating Income stood at $2.4 million in 2022, then jumped by 98.48% to $4.8 million in 2023, then soared by 261.95% to $17.5 million in 2024, then gained by 7.87% to $18.8 million in 2025, then jumped by 36.53% to $25.7 million in 2026.
- Business Quant data shows SCLX's Other Non Operating Income at $25.7 million in Q1 2026, $18.8 million in Q4 2025, and -$58.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.71 Mn |
| Dec 31, 2025 | 18.83 Mn |
| Sep 30, 2025 | -58.36 Mn |
| Jun 30, 2025 | -12.38 Mn |
| Mar 31, 2025 | 10.40 Mn |
| Dec 31, 2024 | 17.46 Mn |
| Sep 30, 2024 | -46,000.00 |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | -457,000.00 |
| Dec 31, 2023 | 4.82 Mn |
| Jun 30, 2023 | -82,000.00 |
| Mar 31, 2023 | -5.25 Mn |
| Dec 31, 2022 | 2.43 Mn |
| Sep 30, 2022 | 33.43 Mn |
| Mar 31, 2022 | 7.50 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 1.16 Mn |
| Jun 30, 2021 | 68,400.00 |
| Mar 31, 2021 | -2.60 Mn |